Acorda Therapeutics (ACOR) Misses Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Therapeutics, Inc. (ACOR) PT Raised to $25 at Jefferies; 2-3 Interesting Call Option Catalysts Coming
November 1, 2017 7:47 AM EDTJefferies raised its price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) to $25.00 (from $22.00) while maintaining a Hold rating. Analyst Michael Yee noted the company reported a light Q3 but mostly from inventory and thus reiterated 2017 revenue guidance.
Over the next 6-12 months, they company will have 3 events that could move... More
